(Q36174872)

12 August 2017

1 reference

title

When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients (English)

1 reference

12 August 2017

anti-retroviral agent

0 references

Robert S Hogg

2

0 references

Evan Wood

series ordinal

1

object named as

Evan Wood

1 reference

12 August 2017

4

Julio S G Montaner

1 reference

12 August 2017

3

P Richard Harrigan

1 reference

PubMed ID

15978527

12 August 2017

language of work or name

1 reference

1 July 2005

1 reference

Lancet Infectious Diseases

12 August 2017

1 reference

12 August 2017

5

1 reference

12 August 2017

7

1 reference

12 August 2017

407-414

1 reference

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

12 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Immunodeficiency and the risk of death in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Antiretroviral treatment in 1998.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Effect of adherence to newly initiated antiretroviral therapy on plasma viral load

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Decline in deaths from AIDS due to new antiretrovirals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Time to hit HIV, early and hard.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Latent reservoirs of HIV: obstacles to the eradication of virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Adherence to HAART among patients with HIV: breakthroughs and barriers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Adherence to triple therapy and viral load response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Treatment of antiretroviral-drug-resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

When To Start Therapy for HIV Infection: A Swinging Pendulum in Search of Data

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Therapy for early HIV infection: how far back should the pendulum swing?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 × 109 cells/L

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

CD4 cell counts in adults with newly diagnosed HIV infection: results of surveillance in England and Wales, 1990-1998. CD4 Surveillance Scheme Advisory Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

The case for earlier treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Sex differences in HIV-1 viral load and progression to AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Initial plasma HIV-1 RNA levels and progression to AIDS in women and men

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Virologic, Immunologic, and Clinical Response to Highly Active Antiretroviral Therapy: the Gender Issue Revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Causes of death in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Opioid substitution and HIV/AIDS treatment and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Genotypic and phenotypic characterization of HIV-1 patients with primary infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Virologic and immunologic values allowing safe deferral of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/μL

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Predictors of optimal virological response to potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Combination antiretroviral therapy and the risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Deciding life and death in the courtroom: debate and clarification

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

One world, one hope: the cost of providing antiretroviral therapy to all nations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

HIV and hepatitis C virus co-infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Hepatotoxicity after introduction of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Strategies for long-term success in the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

The Impact of Adherence on CD4 Cell Count Responses Among HIV-Infected Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Provider assessment of adherence to HIV antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

When should we delay highly active antiretroviral therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Readiness for HIV treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Trust and the acceptance of and adherence to antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Medication adherence strategies for drug abusers with HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

Impact of accessing methadone on the time to initiating HIV treatment among antiretroviral-naive HIV-infected injection drug users

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970162-6

7 January 2021

10.1016/S1473-3099(05)70162-6

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15978527